News

Depomed’s Phase III registration program for Serada in menopausal hot flashes includes two randomized, double-blind, placebo-controlled studies of approximately 540 patients per study. The treatment duration of the

Under the terms of the agreement, Nitten is responsible for securing regulatory approval and has exclusive rights to commercialize AzaSite for ocular bacterial infection in Japan and Taiwan.

DiaMedica, a drug discovery and development company, has reported top-line results of a proof-of-concept Phase IIa trial for DM-99, the company’s third drug in clinical development for type

HemaQuest Pharmaceuticals, a biopharmaceutical company, has received two orphan medicinal product designations from the European Commission for its product HQK-1001 for the treatment of sickle cell disease and

Acacia Pharma, a UK-based pharmaceutical company, has initiated a Phase IIa study of its product APD209 to treat cachexia in cancer patients. According to Acacia, APD209 has been

Alliance HealthCard, a provider of health discount and lifestyle benefits, has completed its acquisition of Access Plans USA. Access Plans markets health insurance and develops and distributes consumer-driven

Genzyme, a biotechnology company, has entered into an agreement to acquire the worldwide rights to Campath from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization

Biolase Technology, a dental laser company, and National Laser Technology have reached a final settlement agreement resolving the claims and counterclaims in the lawsuit between NLT and Biolase

Shire has previously inked a deal with Glaxosmithkline (GSK) to co-promote Vyvanse, Shire’s new drug for the treatment of attention deficit and hyperactivity disorder. The agreement is expected